肺腺癌EGFR-TKI失败后的治疗策略

顾阳春 已出版文章查询
顾阳春
本平台内已出版文章查询
1 曹宝山 已出版文章查询
曹宝山
本平台内已出版文章查询
1 马力文 已出版文章查询
马力文
本平台内已出版文章查询
1

+ 作者地址

1北京大学第三医院肿瘤化疗与放射病科,北京,100191


0
  • 摘要
  • 参考文献
  • 相关文章
  • 统计
肺腺癌的治疗因表皮生长因子受体酪氨酸激酶抑制剂( epidermal growth factor receptor-tyrosine kinase in-hibitor, EGFR-TKI)的出现而率先步入靶向治疗时代,而一代可逆性EGFR-TKI的耐药成为不可避免的挑战。对EGFR信号通路内部和外部异常的深入研究是应对EGFR-TKI耐药的根本,在此基础上开发了二代不可逆性EGFR-TKI、多靶点TKI以及其他多种靶向药物。综合应用靶向药物、化疗和放疗等多种治疗方式,寻找最佳结合模式,对延长患者生存也有重要作用。

[1] Jackman D;Pao W;Riely G .Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.[J].Journal of Clinical Oncology,2010(2):357-360.

[2] Cheng L;Zhang S;Alexander R;Yao Y;MacLennan GT;Pan CX;Huang J;Wang M;Montironi R;Lopez Beltran A .The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.[J].Future oncology,2011(4):519-541.

[3] Oh JE;An CH;Yoo NJ;Lee SH .Detection of low-level EGFR T790M mutation in lung cancer tissues.[J].APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica,2011(7):403-411.

[4] Arcila ME;Oxnard GR;Nafa K;Riely GJ;Solomon SB;Zakowski MF;Kris MG;Pao W;Miller VA;Ladanyi M .Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay.[J].Clinical cancer research: an official journal of the American Association for Cancer Research,2011(5):1169-1180.

[5] Sequist LV;Waltman BA;Dias-Santagata D et al.Gen-otypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors[J].Sci Transl Med,2011,3(75):75ra26.

[6] Kancha RK;Peschel C;Duyster J .The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011(2):387-392.

[7] Yasuda H;Kobayashi S;Costa DB .EGFR exon 20 inser-tion mutations in non-small-cell lung cancer:preclinical data and clinical implications[J].LANCET ONCOLOGY,2011,13(01):e23-e31.

[8] Ou,S.H.I. .Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence[J].Critical reviews in oncology/hematology,2012(3):407-421.

[9] Chang JW;Liu HP;Yu TF;Chiu YT;Hsieh JJ;Chen YT;Chen YR;Wu HD;Huang SF .Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011(12):2027-2035.

[10] Takezawa K;Pirazzoli V;Arcila ME et al.HER2 am-plification:a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation[J].Cancer Discovery,2012,2(10):922-933.

[11] Hurbin A;Wislez M;Busser B;Antoine M;Tenaud C;Rabbe N;Dufort S;de Fraipont F;Moro Sibilot D;Cadranel J;Coll JL;Brambilla E .Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.[J].Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland,2011(1):83-95.

[12] Custodio,A.;Méndez,M.;Provencio,M. .Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications[J].Cancer Treatment Reviews,2012(1):36-53.

[13] Vakiani E;Solit DB .KRAS and BRAF:drug targets and predictive biomarkers[J].Journal of Pathology,2011,223(02):219-229.

[14] Ludovini V;Bianconi F;Pistola L;Chiari R;Minotti V;Colella R;Giuffrida D;Tofanetti FR;Siggillino A;Flacco A;Baldelli E;Iacono D;Mameli MG;Cavaliere A;Crino L .Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011(4):707-715.

[15] Giaccone G;Wang Y .Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.[J].Cancer Treatment Reviews,2011(6):456-464.

[16] Metro G;Duranti S;Chiari R et al.KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)in EGFR wild type(WT)advanced non-small cell lung cancer(NSCLC)patients(pts)[J].Journal of Clinical Oncology,2012,30(Suppl):e18023.

[17] Chaft,J.E.;Arcila,M.E.;Paik,P.K.;Lau,C.;Riely,G.J.;CatherinePietanza,M.;Zakowski,M.F.;Rusch,V.;Sima,C.S.;Ladanyi,M.;Kris,M.G. .Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling[J].Molecular cancer therapeutics,2012(2):485-491.

[18] Uramoto H;Shimokawa H;Hanagiri T;Kuwano M;Ono M .Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(3):361-365.

[19] Suda K;Tomizawa K;Fujii M;Murakami H;Osada H;Maehara Y;Yatabe Y;Sekido Y;Mitsudomi T .Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011(7):1152-1161.

[20] Chang TH;Tsai MF;Su KY;Wu SG;Huang CP;Yu SL;Yu YL;Lan CC;Yang CH;Lin SB;Wu CP;Shih JY;Yang PC .Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.[J].American journal of respiratory and critical care medicine,2011(8):1071-1079.

[21] Chen YJ;Huang WC;Wei YL et al.Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells[J].PLoS One,2011,6(06):e21428.

[22] Bryant JL;Britson J;Balko JM;Willian M;Timmons R;Frolov A;Black EP .A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT.[J].The British journal of cancer,2012(1):148-156.

[23] Lee,M.-S.;Kim,H.-P.;Kim,T.-Y.;Lee,J.W. .Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition[J].Biochimica et biophysica acta. Molecular cell research,2012(2):514-523.

[24] Hegedüs,C.;Truta-Feles,K.;Antalffy,G.;Várady,G.;Német,K.;?zvegy-Laczka,C.;Kéri,G.;Orfi,L.;Szakács,G.;Settleman,J.;Váradi,A.;Sarkadi,B. .Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: Implications for the emergence and reversal of cancer drug resistance[J].Biochemical Pharmacology,2012(3):260-267.

[25] Okamoto K;Okamoto I;Hatashita E;Kuwata K;Yamaguchi H;Kita A;Yamanaka K;Ono M;Nakagawa K .Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.[J].Molecular cancer therapeutics,2012(1):204-213.

[26] Hata A;Katakami N;Yoshioka H;Fujita S;Kunimasa K;Nanjo S;Otsuka K;Kaji R;Tomii K;Iwasaku M;Nishiyama A;Hayashi H;Morita S;Ishida T .Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(2):268-273.

[27] Miller VA;Hirsh V;Cadranal J .Subgroup analysis of LUX-Lung 1:a randomized phase Ⅲ trial of afatinib(BIBW 2992)+ best supportive care(BSC)versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib[J].J Thorac On-col,2010,5(12 Suppl 7):S557-S558.

[28] Campbell A;Reckamp KL;Camidge DR et al.PF-00299804(PF299)patient(pt)-reported outcomes(PROs)and efficacy in adenocarcinoma(adeno)and non-adeno non-small cell lung cancer(NSCLC):A phase(P)II trial in advanced NSCLC after failure of chemotherapy(CT)and erlotinib(E)[J].J Clin Oncol(Meeting Ab-stracts),2010,28(15 Suppl):7596.

[29] Morgillo F;Martinelli E;Troiani T et al.Antitumor ac-tivity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors[J].PLoS One,2011,6(12):e28841.

[30] Dienstmann,R.;DeDosso,S.;Felip,E.;Tabernero,J. .Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer[J].Molecular oncology,2012(1):15-26.

[31] Johnson ML;Riely GJ;Rizvi NA;Azzoli CG;Kris MG;Sima CS;Ginsberg MS;Pao W;Miller VA .Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2011(6):1128-1131.

[32] Janjigian YY;Azzoli CG;Krug LM;Pereira LK;Rizvi NA;Pietanza MC;Kris MG;Ginsberg MS;Pao W;Miller VA;Riely GJ .Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib.[J].Clinical cancer research: an official journal of the American Association for Cancer Research,2011(8):2521-2527.

[33] Schiller JH;Akerley WL;Brugger W et al.Results from ARQ 197-209:A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR in-hibitor-naive patients with locally advanced or metastatic non-small cell lung cancer(NSCLC)[J].Journal of Clinical Oncology,2010,28(18 Suppl):LBA7502.

[34] Normant E;Paez G;West KA;Lim AR;Slocum KL;Tunkey C;McDougall J;Wylie AA;Robison K;Caliri K;Palombella VJ;Fritz CC .The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.[J].Oncogene,2011(22):2581-2586.

[35] Kobayashi,N.;Toyooka,S.;Soh,J.;Yamamoto,H.;Dote,H.;Kawasaki,K.;Otani,H.;Kubo,T.;Jida,M.;Ueno,T.;Ando,M.;Ogino,A.;Kiura,K.;Miyoshi,S. .The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2012(2):161-166.

[36] Morgillo F;D'Aiuto E;Troiani T;Martinelli E;Cascone T;De Palma R;Orditura M;De Vita F;Ciardiello F .Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(3):283-290.

[37] Donev IS;Wang W;Yamada T;Li Q;Takeuchi S;Matsumoto K;Yamori T;Nishioka Y;Sone S;Yano S .Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer.[J].Clinical cancer research: an official journal of the American Association for Cancer Research,2011(8):2260-2269.

[38] Felip E;Gridelli C;Baas P;Rosell R;Stahel R .Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.[J].Annals of oncology: official journal of the European Society for Medical Oncology,2011(7):1507-1519.

[39] Sun L;Zhang Q;Luan H et al.Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases:implications for clinical practice[J].Journal of Experimental and Clinical Cancer Research,2011,30:30.

[40] Iwai,T.;Moriya,Y.;Shirane,M.;Fujimoto-Ouchi,K.;Mori,K. .Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts[J].Oncology reports,2012(4):923-928.

[41] Suda,K.;Tomizawa,K.;Osada,H.;Maehara,Y.;Yatabe,Y.;Sekido,Y.;Mitsudomi,T. .Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2012(3):292-299.

[42] Giaccone G;Herbst RS;Manegold C;Scagliotti G;Rosell R;Miller V;Natale RB;Schiller JH;Von Pawel J;Pluzanska A;Gatzemeier U;Grous J;Ochs JS;Averbuch SD;Wolf MK;Rennie P;Fandi A;Johnson DH .Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.[J].Journal of Clinical Oncology,2004(5):777-784.

[43] Herbst RS;Giaccone G;Schiller JH;Natale RB;Miller V;Manegold C;Scagliotti G;Rosell R;Oliff I;Reeves JA;Wolf MK;Krebs AD;Averbuch SD;Ochs JS;Grous J;Fandi A;Johnson DH .Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.[J].Journal of Clinical Oncology,2004(5):785-794.

[44] Herbst RS;Prager D;Hermann R;Fehrenbacher L;Johnson BE;Sandler A;Kris MG;Tran HT;Klein P;Li X;Ramies D;Johnson DH;Miller VA .TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.[J].Journal of Clinical Oncology,2005(25):5892-5899.

[45] Gatzemeier U;Pluzanska A;Szczesna A;Kaukel E;Roubec J;De-Rosa F;Milanowski J;Karnicka-Mlodkowski H;Pesek M;Serwatowski P;Ramlau R;Janaskova T;Vansteenkiste J;Strausz J;Manikhas GM;Von-Pawel J .Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.[J].Journal of Clinical Oncology,2007(12):1545-1552.

[46] Mok T;Wu YL;Thongprasert S et al.A randomized placebo-controlled phase Ⅲ study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer(NSCLC):FASTACT-II[J].Journal of Clinical Oncology,2012,30:Abstr7519.

[47] Mumenthaler SM;Foo J;Leder K;Choi NC;Agus DB;Pao W;Mallick P;Michor F .Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.[J].Molecular pharmaceutics,2011(6):2069-2079.

[48] Davies AM;Ho C;Beckett L;Lau D;Scudder SA;Lara PN;Perkins N;Gandara DR .Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.[J].Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2009(7):862-868.

[49] Riely GJ;Rizvi NA;Kris MG;Milton DT;Solit DB;Rosen N;Senturk E;Azzoli CG;Brahmer JR;Sirotnak FM;Seshan VE;Fogle M;Ginsberg M;Miller VA;Rudin CM .Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.[J].Journal of Clinical Oncology,2009(2):264-270.

[50] Cheng H;An SJ;Dong S et al.Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib[J].J Hematol Oncol,2011,4:5.

[51] Pan F;Tian J;Zhang X;Zhang Y;Pan Y .Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.[J].Journal of Cancer Research and Clinical Oncology,2011(9):1397-1408.

[52] Jiang,Y.;Li,C.;Ma,Y.;Chen,J.;Li,Y.;Chen,L. .The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines[J].Clinical laboratory,2012(5/6):551-561.

[53] Shukuya T;Takahashi T;Naito T;Kaira R;Ono A;Nakamura Y;Tsuya A;Kenmotsu H;Murakami H;Harada H;Mitsuya K;Endo M;Nakasu Y;Takahashi K;Yamamoto N .Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(3):457-461.

[54] Chang CC;Chi KH;Kao SJ;Hsu PS;Tsang YW;Chang HJ;Yeh YW;Hsieh YS;Jiang JS .Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2011(2):189-194.

[55] Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer[J].Lung cancer: Journal of the International Association for the Study of Lung Cancer,2013(1):33-39.

[56] Chaft JE;Oxnard GR;Sima CS;Kris MG;Miller VA;Riely GJ .Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.[J].Clinical cancer research: an official journal of the American Association for Cancer Research,2011(19):6298-6303.



期刊热词
  • + 更多
  • 字体大小